comparemela.com

Latest Breaking News On - Jaume capdevila - Page 1 : comparemela.com

Investegate |ITM Isotope Technologies Munic Announcements | ITM Isotope Technologies Munic: ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference

Investegate announcements from ITM Isotope Technologies Munic, ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference

United statesUppsala lanComunidad autonoma de catalunaJaume capdevilaBen orzelekJulia hofmann svenjaWolfgang weberAldo scarpaHeloisa soaresUppsala universityHospital trust of veronaHebron university hospitalUniversity of utahEuropean neuroendocrine tumor societyTechnical university of munichCorporate communications

ITM to Present Phase III COMPOSE Poster and Host Satellite

Garching / Munich, March 16, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical theranostics company, today announced that the.

United statesUppsala lanComunidad autonoma de catalunaJaume capdevilaBen orzelekJulia hofmann svenjaWolfgang weberAldo scarpaHeloisa soaresUppsala universityHospital trust of veronaHebron university hospitalUniversity of utahEuropean neuroendocrine tumor societyTechnical university of munichCorporate communications

ITM Isotope Technologies Munich SE: ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference

Garching / Munich, March 16, 2023 - ITM Isotope Technologies Munich SE) in a poster presentation at the 20th Annual European Neuroendocrine Tumor Society(n.c.a. 177Lu-edotreotide) compared to standard

United statesUppsala lanComunidad autonoma de catalunaDennis riedlJaume capdevilaBen orzelekJulia hofmann svenjaWolfgang weberAldo scarpaHeloisa soaresUppsala universityHospital trust of veronaHebron university hospitalUniversity of utahEuropean neuroendocrine tumor societyTechnical university of munich

Ipsen: European Commission Approves Cabometyx as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer Seite 1

03.05.2022 - Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission (EC) has approved the use of Cabometyx (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic . Seite 1

Israel generalComunidad autonoma de catalunaJaume capdevilaIpsen euronextHebron university hospitalHebron institute of oncologyEuropean commissionRegulatory newsMedical oncologistHebron institute

Ipsen: European Commission Approves Cabometyx as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Approval based on data from the COSMIC-311 Phase III trial, in which Cabometyx (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1 This milestone

Israel generalFrance generalUnited statesUnited kingdomHong kongNew zealandSouth koreaComunidad autonoma de catalunaDominican republicSaudi arabiaGreat britainRussian federationJaume capdevilaGemma roperIpsen euronextHebron university hospital

vimarsana © 2020. All Rights Reserved.